n-acetyl-glucosamine thiazoline

N-Acetyl-glucosamine thiazoline (NAG-thiazoline) is a synthetic small molecule analog of the oxazolinium bicyclic intermediate formed during the enzymatic conversion of N-acetylglucosamine to 1,6-anhydro-N-acetylmuramic acid. It acts as a potent inhibitor of most β-acetylglucosaminidases (β-GlcNAcases), except for insect and bacterial chitinolytic β-GlcNAcase, by mimicking the transition state in substrate-assisted catalysis. This compound has been explored as a tool compound and potential therapeutic agent, particularly for its ability to inhibit enzymes involved in glycan processing and bacterial cell wall biosynthesis. It has received orphan drug designation for the treatment of adult Tay-Sachs disease but is not FDA approved[1][2][3][6].

Other names

N-acetylglucosamine thiazoline179030-22-9UNII-ML5FHL557AUNII-ML-5FHL557AUNII-ML 5FHL557A